Sarah Canetta, Ph.D., and Christoph Kellendonk, Ph.D.
Dr. Canetta is Associate Research Scientist and Dr. Kellendonk is Assistant Professor of Pharmacology (in Psychiatry), Departments of Psychiatry & Pharmacology, Columbia University, and the Division of Molecular Therapeutics, New York State Psychiatric Institute, New York.
Within the past 12 months, Drs. Canetta and Kellendonk have no conflicts of interest relevant to this activity.
Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.
Estimated time to complete:
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®
, you should be able to:
- Describe aspects of cognitive functioning that are impaired in schizophrenia, with a particular focus on prefrontal cortex-dependent domains such as working memory and attentional set-shifting;
- Delineate several major elements of the neural circuitry that contribute to working memory and attentional set-shifting under normal conditions and that may be compromised in schizophrenia;
- Describe several of the neuromodulatory systems within the prefrontal cortex that contribute to working memory and attentional set-shifting under normal conditions and that may be compromised in schizophrenia;
- Discuss several emerging areas of therapeutics to treat cognitive dysfunction in schizophrenia.